Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy.

Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy.

Item
http://www.wikidata.org/entity/Q40234121
Design, synthesis, and evaluation of duocarmycin O-amino phenol prodrugs subject to tunable reductive activationA five-membered lactone prodrug of CBI-based analogs of the duocarmycinsA novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct.A unique class of duocarmycin and CC-1065 analogues subject to reductive activation.Efficacious cyclic N-acyl O-amino phenol duocarmycin prodrugs.Synthesis and biological evaluation of a novel pentagastrin-toxin conjugate designed for a targeted prodrug mono-therapy of cancer.Glucose conjugation for the specific targeting and treatment of cancer.Peptide modified mesoporous silica nanocontainers.New thiazacridine agents: Synthesis, physical and chemical characterization, and in vitro anticancer evaluation.Determination of the biological activity and structure activity relationships of drugs based on the highly cytotoxic duocarmycins and CC-1065The first generation of β-galactosidase-responsive prodrugs designed for the selective treatment of solid tumors in prodrug monotherapy.Duocarmycin analogues target aldehyde dehydrogenase 1 in lung cancer cells.A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells.Selective treatment of hypoxic tumor cells in vivo: phosphate pre-prodrugs of nitro analogues of the duocarmycins.Investigation of the transformations of a novel anti-cancer agent combining HPLC, HPLC-MS and direct ESI-HRMS analyses.Novel hypoxia-targeting Pt(iv) prodrugs.The two faces of potent antitumor duocarmycin-based drugs: a structural dissection reveals disparate motifs for DNA versus aldehyde dehydrogenase 1 affinity.
P2860

Antitumor agents: development of highly potent glycosidic duocarmycin analogues for selective cancer therapy.

Item
http://www.wikidata.org/entity/Q40234121
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Antitumor agents: development ...... for selective cancer therapy.
@en
type
label
Antitumor agents: development ...... for selective cancer therapy.
@en
prefLabel
Antitumor agents: development ...... for selective cancer therapy.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
Antitumor agents: development ...... for selective cancer therapy.
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698